Syndax Pharmaceuticals (SNDX) Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SNDX shares.
View SNDX analyst ratings or view top-rated stocks.

6 Wall Street analysts have issued twelve-month price targets for Syndax Pharmaceuticals' stock. Their SNDX share price forecasts range from $31.00 to $37.00. On average, they anticipate the company's share price to reach $33.86 in the next twelve months. This suggests a possible upside of 65.4% from the stock's current price.
View analysts price targets for SNDX or view top-rated stocks among Wall Street analysts.

Syndax Pharmaceuticals' stock was trading at $25.45 at the beginning of the year. Since then, SNDX shares have decreased by 19.6% and is now trading at $20.47.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our SNDX earnings forecast.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) issued its earnings results on Monday, May, 8th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.02.

ETFs with the largest weight of Syndax Pharmaceuticals (NASDAQ:SNDX) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC) and iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU).

(SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

Syndax Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (10.22%), BlackRock Inc. (7.15%), State Street Corp (5.62%), Jennison Associates LLC (3.53%), BVF Inc. IL (3.11%) and Dimensional Fund Advisors LP (1.93%). Insiders that own company stock include Alexander Nolte, Briggs Morrison, Dennis Podlesak, Fabrice Egros, Keith Katkin, Michael A Metzger, Michael L Meyers, Peter Ordentlich and Pierre Legault.
View institutional ownership trends.

Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SNDX stock can currently be purchased for approximately $20.47.

Syndax Pharmaceuticals (NASDAQ:SNDX) has a market capitalization of $1.41 billion and generates $139.71 million in revenue each year. The company earns $-149,340,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis.

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The official website for the company is www.syndax.com. The company can be reached via phone at (781) 419-1400, via email at ir@syndax.com, or via fax at 781-419-1420.